Bone Marrow Stromal Cells Associated with Poly L-Lactic-Co-Glycolic Acid (PLGA) Nanofiber Scaff old Improve Transected Sciatic Nerve Regeneration

Bone Marrow Stromal Cells Associated with Poly L-Lactic-Co-Glycolic Acid (PLGA) Nanofi ber Scaff old Improve Transected Sciatic Nerve Regeneration

Background: Although peripheral nerves show capacity for regeneration after injury to a certain extent, the extent of regeneration is not remarkable. Previous studies have suggested that through the production of growth factors or extracellular matrix components, mesenchymal stem cells may enhance nerve regeneration.Objectives: In the present study, the therapeutic potenc...

Poly (Lactic-Co-Glycolic) Acid (PLGA) Adjuvant for Immunotherapy

Nowadays, there are several efforts in immunotherapy especially biodegradable and biocompatible nano-polymers are using as immunomodulatory to induce cell mediated immune responses [1]. The advantages of nanoparticles have been proved to be potent immunomodulators in several kinds of vaccines to control a release of antigen, higher quality and quantity of immune responses and protect the integr...

Poly(lactic-co-glycolic acid) conduit for repair of injured sciatic nerve: A mechanical analysis

Tensile stress and tensile strain directly affect the quality of nerve regeneration after bridging nerve defects by poly(lactic-co-glycolic acid) conduit transplantation and autogenous nerve grafting for sciatic nerve injury. This study collected the sciatic nerve from the gluteus maximus muscle from fresh human cadaver, and established 10-mm-long sciatic nerve injury models by removing the isc...

Accuracy of Motor Axon Regeneration Across Single lumen and Multi-channel Poly(lactic-co-glycolic Acid) (PLGA) Nerve Tubes

An Overview of Poly(lactic-co-glycolic) Acid (PLGA)-Based Biomaterials for Bone Tissue Engineering

Poly(lactic-co-glycolic) acid (PLGA) has attracted considerable interest as a base material for biomedical applications due to its: (i) biocompatibility; (ii) tailored biodegradation rate (depending on the molecular weight and copolymer ratio); (iii) approval for clinical use in humans by the U.S. Food and Drug Administration (FDA); (iv) potential to modify surface properties to provide better ...